Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
Objectives To systematically review the literature for assay methods that aim to evaluate type I interferon (IFN-I) pathway activation and to harmonise-related terminology.Methods Three databases were searched for reports of IFN-I and rheumatic musculoskeletal diseases. Information about the perform...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-03-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/9/1/e002876.full |
| _version_ | 1811160236971524096 |
|---|---|
| author | Mary K Crow Lars Rönnblom Dimitrios T Boumpas Robert Biesen George Bertsias Marie-Louise Frémond Marie Wahren-Herlenius Giulio Cavalli PG Conaghan Maija-Leena Eloranta Javier Rodríguez-Carrio Marianne Visser Agata Burska Willem A Dik Ed Vital Jan Rehwinkel Marjan Versnel |
| author_facet | Mary K Crow Lars Rönnblom Dimitrios T Boumpas Robert Biesen George Bertsias Marie-Louise Frémond Marie Wahren-Herlenius Giulio Cavalli PG Conaghan Maija-Leena Eloranta Javier Rodríguez-Carrio Marianne Visser Agata Burska Willem A Dik Ed Vital Jan Rehwinkel Marjan Versnel |
| author_sort | Mary K Crow |
| collection | DOAJ |
| description | Objectives To systematically review the literature for assay methods that aim to evaluate type I interferon (IFN-I) pathway activation and to harmonise-related terminology.Methods Three databases were searched for reports of IFN-I and rheumatic musculoskeletal diseases. Information about the performance metrics of assays measuring IFN-I and measures of truth were extracted and summarised. A EULAR task force panel assessed feasibility and developed consensus terminology.Results Of 10 037 abstracts, 276 fulfilled eligibility criteria for data extraction. Some reported more than one technique to measure IFN-I pathway activation. Hence, 276 papers generated data on 412 methods. IFN-I pathway activation was measured using: qPCR (n=121), immunoassays (n=101), microarray (n=69), reporter cell assay (n=38), DNA methylation (n=14), flow cytometry (n=14), cytopathic effect assay (n=11), RNA sequencing (n=9), plaque reduction assay (n=8), Nanostring (n=5), bisulphite sequencing (n=3). Principles of each assay are summarised for content validity. Concurrent validity (correlation with other IFN assays) was presented for n=150/412 assays. Reliability data were variable and provided for 13 assays. Gene expression and immunoassays were considered most feasible. Consensus terminology to define different aspects of IFN-I research and practice was produced.Conclusions Diverse methods have been reported as IFN-I assays and these differ in what elements or aspects of IFN-I pathway activation they measure and how. No ‘gold standard’ represents the entirety of the IFN pathway, some may not be specific for IFN-I. Data on reliability or comparing assays were limited, and feasibility is a challenge for many assays. Consensus terminology should improve consistency of reporting. |
| first_indexed | 2024-04-10T05:54:16Z |
| format | Article |
| id | doaj.art-acf1dfeb0fa4419ca571c1658790fe65 |
| institution | Directory Open Access Journal |
| issn | 2056-5933 |
| language | English |
| last_indexed | 2024-04-10T05:54:16Z |
| publishDate | 2023-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj.art-acf1dfeb0fa4419ca571c1658790fe652023-03-03T22:30:08ZengBMJ Publishing GroupRMD Open2056-59332023-03-019110.1136/rmdopen-2022-002876Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to considerMary K Crow0Lars Rönnblom1Dimitrios T Boumpas2Robert Biesen3George Bertsias4Marie-Louise Frémond5Marie Wahren-Herlenius6Giulio Cavalli7PG Conaghan8Maija-Leena Eloranta9Javier Rodríguez-Carrio10Marianne Visser11Agata Burska12Willem A Dik13Ed Vital14Jan Rehwinkel15Marjan Versnel16Hospital for Special Surgery, Weill Cornell Medical College, Mary Kirkland Center for Lupus Research, New York, USAUppsala University, Department of Medical Sciences, Rheumatology, Uppsala, SwedenUniversity of Crete, Medical School, Department of Rheumatology-Clinical Immunology, Heraklion, GreeceCharité University Medicine Berlin, Department of Rheumatology, Berlin, GermanyUniversity of Crete, Medical School, Department of Rheumatology-Clinical Immunology, Heraklion, GreeceUniversité de Paris Cité, Hôpital Necker-Enfants Malades, Immuno-Hématologie et Rhumatologie pédiatriques, Paris, FranceKarolinska Institutet, Division of Rheumatology, Stockholm, SwedenUnit of Immunology, Rheumatology, Allergy and Rare Diseases, Vita-Salute San Raffaele University, Milan, ItalyLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, UKUppsala University, Department of Medical Sciences, Rheumatology, Uppsala, SwedenUniversity of Oviedo, Area of Immunology, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, SpainUniversity of Crete, Medical School, Department of Internal Medicine, Heraklion, GreeceLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, UKErasmus MC, University Medical Center Rotterdam, Laboratory Medical Immunology, Department of Immunology, Rotterdam, Netherlands Immunology, Rotterdam, The NetherlandsLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, UKMedical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, UKErasmus MC, Department of Immunology, Rotterdam, The NetherlandsObjectives To systematically review the literature for assay methods that aim to evaluate type I interferon (IFN-I) pathway activation and to harmonise-related terminology.Methods Three databases were searched for reports of IFN-I and rheumatic musculoskeletal diseases. Information about the performance metrics of assays measuring IFN-I and measures of truth were extracted and summarised. A EULAR task force panel assessed feasibility and developed consensus terminology.Results Of 10 037 abstracts, 276 fulfilled eligibility criteria for data extraction. Some reported more than one technique to measure IFN-I pathway activation. Hence, 276 papers generated data on 412 methods. IFN-I pathway activation was measured using: qPCR (n=121), immunoassays (n=101), microarray (n=69), reporter cell assay (n=38), DNA methylation (n=14), flow cytometry (n=14), cytopathic effect assay (n=11), RNA sequencing (n=9), plaque reduction assay (n=8), Nanostring (n=5), bisulphite sequencing (n=3). Principles of each assay are summarised for content validity. Concurrent validity (correlation with other IFN assays) was presented for n=150/412 assays. Reliability data were variable and provided for 13 assays. Gene expression and immunoassays were considered most feasible. Consensus terminology to define different aspects of IFN-I research and practice was produced.Conclusions Diverse methods have been reported as IFN-I assays and these differ in what elements or aspects of IFN-I pathway activation they measure and how. No ‘gold standard’ represents the entirety of the IFN pathway, some may not be specific for IFN-I. Data on reliability or comparing assays were limited, and feasibility is a challenge for many assays. Consensus terminology should improve consistency of reporting.https://rmdopen.bmj.com/content/9/1/e002876.full |
| spellingShingle | Mary K Crow Lars Rönnblom Dimitrios T Boumpas Robert Biesen George Bertsias Marie-Louise Frémond Marie Wahren-Herlenius Giulio Cavalli PG Conaghan Maija-Leena Eloranta Javier Rodríguez-Carrio Marianne Visser Agata Burska Willem A Dik Ed Vital Jan Rehwinkel Marjan Versnel Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider RMD Open |
| title | Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider |
| title_full | Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider |
| title_fullStr | Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider |
| title_full_unstemmed | Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider |
| title_short | Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider |
| title_sort | type i interferon pathway assays in studies of rheumatic and musculoskeletal diseases a systematic literature review informing eular points to consider |
| url | https://rmdopen.bmj.com/content/9/1/e002876.full |
| work_keys_str_mv | AT marykcrow typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT larsronnblom typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT dimitriostboumpas typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT robertbiesen typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT georgebertsias typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT marielouisefremond typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT mariewahrenherlenius typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT giuliocavalli typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT pgconaghan typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT maijaleenaeloranta typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT javierrodriguezcarrio typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT mariannevisser typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT agataburska typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT willemadik typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT edvital typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT janrehwinkel typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider AT marjanversnel typeiinterferonpathwayassaysinstudiesofrheumaticandmusculoskeletaldiseasesasystematicliteraturereviewinformingeularpointstoconsider |